Hospitals accounted for $39.6 billion of that spending, marking 8.4 percent growth from 2020. Clinics accounted for $105 billion, a 7.7 percent increase
Gilead’s COVID-19 therapeutic remdesivir made up nearly 10 percent of what hospitals spent on drugs in 2021. Hospitals’ remdesivir spending outpaced the next three drugs combined, according to the study.
“The drug-spending whiplash that clinics and hospitals experienced in the first year of the pandemic did not end with 2021,” Eric Tichy, PharmD, division chair of supply chain management at Rochester, Minn.-based Mayo Clinic and lead study author, said in a statement. “Uncertainty remains around how long the federal government will continue to pay for COVID treatments, and around inflation, which is moving through most economic sectors.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.